英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
plopped查看　plopped　在百度字典中的解释百度英翻中〔查看〕
plopped查看　plopped　在Google字典中的解释Google英翻中〔查看〕
plopped查看　plopped　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Treatment in Advanced NSCLC | LIBTAYO® (cemiplimab-rwlc)
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced non-small cell lung cancer (NSCLC) Review Important Safety Info Full Prescribing Information including Med Guide
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation (1)
  • Cemiplimab-rwlc - NCI - National Cancer Institute
    FDA label information for this drug is available at DailyMed Use in Cancer Cemiplimab-rwlc is approved to treat adults with: Basal cell carcinoma (BCC) (a type of skin cancer) It is used in patients whose cancer has spread after treatment with hedgehog pathway inhibitor therapy or who cannot receive hedgehog pathway inhibitor therapy Cutaneous squamous cell carcinoma (a type of skin cancer
  • LIBTAYO® Full Prescribing Information | Regeneron
    LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side . . .
    This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment
  • Cemiplimab (Libtayo®) - ChemoExperts
    Treatment Name: Cemiplimab (Libtayo®) Cemiplimab (Libtayo®) is an Immunotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does cemiplimab work? Cemiplimab is designed to block the signals that tumor cells use to suppress the immune system allowing the immune system to attack the lung cancer cells Goals of therapy:
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    About Cemiplimab-rwlc (Libtayo®) The immune system works by creating antibodies, which are proteins that attach to antigens found on the surface of a cell The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell Monoclonal antibodies are created in a lab to attach to the antigens found on specific types of cancer cells
  • LIBTAYO® (cemiplimab-rwlc) for Treatment in Advanced CSCC
    LIBTAYO® (cemiplimab-rwlc) is indicated for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (laCSCC or mCSCC) who are not candidates for curative surgery or curative radiation Review Important Safety Information and full Prescribing Information
  • Libtayo SGM 2757-A - info. caremark. com
    Non-Small Cell Lung Cancer (NSCLC) Libtayo, as a single agent, is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical





中文字典-英文字典  2005-2009